Celonis and Smurfit Westrock Unlock Significant Value by Optimizing Inventory Management with Process Intelligence and AI
8.4.2025 10:00:00 CEST | Business Wire | Press Release
Celonis, the global leader in Process Mining and Process Intelligence, today shared the results of an innovative AI-driven solution that is optimizing Smurfit Westrock’s inventory management, unlocking significant value. Enabled by the Process Intelligence Graph and built on the Celonis Process Intelligence Platform, the AI Copilot is a prime example of how Process Intelligence empowers Artificial Intelligence to deliver tangible business impact.
Building on the impressive achievements, Smurfit Westrock is expanding its collaboration with Celonis to optimize additional core business processes across its global operations.
Unlocking AI’s Full Potential Through Process Intelligence
With operations spanning the globe, an inventory with hundreds of thousands of spare part numbers, and a series of recent acquisitions, Smurfit Westrock faced challenges in mastering data inconsistencies, such as duplicate materials, language inconsistencies, and synonym-based descriptions (e.g., “lubricant” vs. “oil”). These issues resulted in unnecessary inventory buildup, procurement inefficiencies (both upstream and downstream), and higher costs.
Using the Celonis Process Intelligence Graph and large language model (LLM)-based analysis, Smurfit Westrock was able to harmonize its master data, creating a foundation for AI-driven inventory management. The impact was immediate and measurable. Within just two months, Smurfit Westrock identified that many purchase orders were raised for spare parts that were already in stock. Additionally, a significant amount of spare parts had remained unused for over eight years. By leveraging the Celonis Process Intelligence platform, the company is now proactively cancelling unnecessary purchases for excess stock and optimizing stock utilization.
The data harmonization layer provided by Celonis also powers an AI Copilot that optimizes spare parts availability for plant engineers. The Copilot identifies the right materials based on real-time inventory, plant location, and purchasing patterns. Equipped with a natural language interface, the Copilot enables users to query inventory across global facilities in their own words—whether by technical descriptions or common industry terms. This eliminates the need for exact part numbers and simplifies the user experience.
“In August 2024, when one of our European plants had a breakdown, the supplier quoted us a significant delay for the supply of a replacement part,” said Brian Dodson, Business Process Improvement Manager and Celonis Center of Excellence lead at Smurfit Westrock. “With Celonis, we were able to find a plant in the region with the needed part and schedule a transfer order in under a day. This enables us to unlock new levels of efficiency, deliver enhanced value to our maintenance teams, and drive sustainability.”
“The ability to harness AI effectively starts with understanding and optimizing the processes that power a business,” said Rupal Karia, Country Leader UKI & MEA at Celonis. “With Celonis, Smurfit Westrock has been able to tackle challenges like duplicate spare parts, unnecessary procurement and inventory inefficiencies, unlocking tremendous value along the way. We are proud to deepen our partnership and continue helping Smurfit Westrock leverage Process Intelligence and AI to drive measurable impact across its global operations.”
Celonis provides Smurfit Westrock with a strategic roadmap for AI implementation, ensuring that automation initiatives are applied where they can deliver the greatest value. By validating AI opportunities based on process efficiency and human intervention requirements, Smurfit Westrock is maximizing the impact of AI on its operations.
Smurfit Westrock aims to expand its use of Celonis to optimize procurement, maintenance, and production processes across Europe, Latin America, and North America.
Learn more about how the partnership between Smurfit Westrock and Celonis went from small beginnings in the company’s European Finance department to being used across the business by 1,000+ users realizing meaningful value each year.
About Celonis
Celonis makes processes work for people, companies, and the planet. The Celonis Process Intelligence Platform, powered by process mining and AI, combines process data and business context to create a living digital twin of the enterprise, connecting people to processes, teams to each other, and AI to the business. Thousands of companies worldwide, including half of the top 200 companies on the Forbes Global 2000, use Celonis to understand their business, optimize operations and drive significant value across the top, bottom, and green lines.
Celonis is headquartered in Munich, Germany, and New York City, USA, with more than 20 offices worldwide.
© 2025 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250408486252/en/
Contacts
Media Contact
press@celonis.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom